2016

    • September 2, 2016

    Nemaura Medical Inc., sign Letter of Intent with Shenzen CAS Health Corp, for potential JV and manufacture of their sugarBEAT® system

    2nd September 2016, Loughborough, UK. Nemaura Medical Inc. (OTC BB: NMRD),(“Nemaura” or  the “Company”), a medical device company developing...

    Read more
    August 4, 2016

    Nemaura Medical Inc., completes second FDA Pre-submission meeting and appoints Navigant to submit IDE for Nemaura’s sugarBEAT® system

      4th August 2016, Loughborough, UK. Nemaura Medical Inc. (OTC BB: NMRD),(“Nemaura”), a medical device company developing a minimally...

    Read more
    April 15, 2016

    Interim Clinical Data on Increased Measurement Frequency for sugarBEAT® CGM Released by Nemaura Medical

      14th April 2016, Loughborough, UK. Nemaura Medical Inc. (OTC BB: NMRD),(“Nemaura”), a medical device company developing a minimally...

    Read more
    March 15, 2016

    Nemaura Medical Announces receipt of notification of CE Approval for its sugarBEAT® Continuous Glucose Monitoring System

    March 15th, 2016, Loughborough, UK. Nemaura Medical Inc. (OTC BB: NMRD),(“Nemaura”), a medical device company developing a minimally invasive...

    Read more